News Breaks |
|
|
| August 3, 2012 |
| 10:02 EDT |  | NUVA, MDT | NuVasive says patent appeal case to be delayed
Medical device maker NuVasive (NUVA) last night disclosed in a regulatory filing that its appeal of a federal court decision on its patent case against Medtronic (MDT) has been delayed. Specifically, a federal appeals court ruled that royalty rates must be determined by a lower court before NuVasive's appeal can proceed, NuVasive reported. The company expects the lower court to reach a decision in the near-term, and it anticipates that the appeal will subsequently move forward. In a note to investors earlier today, Piper Jaffray analyst Matt Miksic wrote that the lower court's final ruling could be a catalyst for NuVasive, as it will remove an overhang on the stock. In early trading, NuVasive added 0.97% to $19.82. |
|
|
News For NUVA;MDT From The Last 14 Days Check below for free stories on NUVA;MDT the last two weeks. |
|
|
| May 17, 2013 |
| 10:07 EDT |  | NUVA | On The Fly: Analyst Initiation Summary
 Subscribe for More Information |
|
| 06:41 EDT | | NUVA | NuVasive initiated with a Buy at WallachBeth
Subscribe for More Information |
|
| May 16, 2013 |
| 13:32 EDT |  | MDT | Medtronic volatility flat into Q4 and outlook
Subscribe for More Information |
|
| 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 14, 2013 |
| 07:18 EDT |  | NUVA | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. |
|
| May 10, 2013 |
| 15:49 EDT | | MDT | Medtronic defibrillators demonstrate success of shock avoidance
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT | | MDT | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
| May 6, 2013 |
| 09:19 EDT | | MDT | Medtronic receives FDA approval for newest cardiac devices
Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators. |
|
| 08:18 EDT | | NUVA | NuVasive acquires ANC in Dayton, Ohio for $4.5M
Subscribe for More Information |
| |
|
|
|
|
